Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials

Table 6

League table of the LDL-C network meta-analysis results among placebo and 7 statins. (Results with statistical significance are shown in bold.).

	Rosuvastatin	Atorvastatin	Pitavastatin	Simvastatin	Pravastatin	Fluvastatin	Lovastatin	Placebo
Rosuvastatin	Rosuvastatin	5.87 (-5.72, 17.47)	8.26 (-12.46, 28.98)	15.35 (-0.24, 30.95)	16.15 (-2.87, 35.16)	23.03 (-4.12,50.19)	33.67 (-9.49, 76.83)	72.28 (57.08, 87.48)
Atorvastatin	-5.87 (-17.47, 5.72)	Atorvastatin	2.38 (-16.71, 21.48)	9.48 (-2.91, 21.88)	10.27 (-7.68, 28.22)	17.16 (-7.82,42.14)	27.79 (-14.15, 69.74)	66.40 (55.10, 77.71)
Pitavastatin	-8.26 (-28.98, 12.46)	-2.38 (-21.48, 16.71)	Pitavastatin	7.10 (-12.51, 26.71)	7.89 (-14.86, 30.63)	14.78 (-16.04,45.59)	25.41 (-20.05, 70.87)	64.02 (43.17, 84.87)
Simvastatin	-15.35 (-30.95, 0.24)	-9.48 (-21.88, 2.91)	-7.10 (-26.71, 12.51)	Simvastatin	0.79 (-18.99, 20.57)	7.68 (-18.77, 34.12)	18.31 (-24.09, 60.71)	56.92 (44.05, 69.80)
Pravastatin	-16.15 (-35.16, 2.87)	-10.27 (-28.22, 7.68)	-7.89 (-30.63, 14.86)	-0.79 (-20.57, 18.99)	Pravastatin	6.89 (-23.21, 36.99)	17.52 (-27.45, 62.49)	56.13 (36.37, 75.89)
Fluvastatin	-23.03 (-50.19, 4.12)	-17.16 (-42.14, 7.82)	-14.78 (-45.59, 16.04)	-7.68 (-34.12, 18.77)	-6.89 (-36.99, 23.21)	Fluvastatin	10.64 (-36.38, 57.66)	49.25 (25.19, 73.31)
Lovastatin	-33.67 (-76.83, 9.49)	-27.79 (-69.74, 14.15)	-25.41 (-70.87, 20.05)	-18.31 (-60.71, 24.09)	-17.52 (-62.49, 27.45)	-10.64 (-57.66, 36.38)	Lovastatin	38.61 (-1.79, 79.01)
Placebo	-72.28 (-87.48, -57.08)	-66.40 (-77.71, -55.10)	-64.02 (-84.87, -43.17)	-56.92 (-69.80, -44.05)	-56.13 (-75.89, -36.37)	-49.25 (-73.31, -25.19)	-38.61 (-79.01, 1.79)	Placebo